Most likely a reflection of IMU’s expectations from the Azer-cel acquisition. There’s no need to expend effort on alternative CD19 targeting drugs if Azer-cel is looking like it will do the job.
So, I’m notching it up to relationship management… there may be a new version of onCARlytics down the track targeting a different protein which IMU and ALA may be able to collaborate on so I’m sure ALA will appreciate the heads up that their CD19 targeting drug won’t be of use.
Media Thread, page-12420
-
- There are more pages in this discussion • 1,872 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $431.8M | |||
| Open | High | Low | Value | Volume |
| 5.9¢ | 5.9¢ | 5.6¢ | $1.037M | 17.94M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 1882949 | 5.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.9¢ | 399643 | 3 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| IMU (ASX) Chart |